Replies to post #153 on Equity Field Notes from temporal sources

[DanWebzster]

RARE now has 2 FDA-approved drugs: Mepsevii and Crysvita

Q-1/2018 reported cash of $571mn, providing a runway thru the end of 2018.

They sold their priority review voucher and this one-timer is the reason for Q-1 profitability.

RARE may need another equity offering if Crysvita launch goes poorly.